Short sellers are continuing to target biotechnology stocks as one of the frothiest sectors in US equities staggers after a bruising August.» Read More
Aug 31- Asterias Biotherapeutics Inc said initial data from a small study showed that its lead stem cell therapy could improve mobility in patients paralyzed by a spinal cord injury. Asterias bought OPC-1 in 2013 from the erstwhile stem cell research leader Geron Corp, which decided to focus on developing cancer drugs. Asterias is looking to show recovery of...
Discussing which biotechs may have been oversold in the selloff, with Michael Yee, RBC Capital biotech analyst.
Aug 21- The chief executive officer of biotechnology company Northwest Biotherapeutics Inc said on Friday the company has temporarily stopped screening new patients for the late-stage trial of its experimental brain cancer drug. The study, among patients with newly diagnosed brain cancer, is being conducted in Germany, the United Kingdom, the United States...
David Seaburg, Cowen & Company, and Craig Johnson, Piper Jaffray & Co, discuss biotech, a formerly hot sector that's down more than 7 percent in a month.
One biotech stock could see massive moves later this month, thanks to the meddling of hedge fund heavy hitter, Kyle Bass. CNBC's Meg Tirrell reports the latest.
The ETF that tracks biotechs, BBH, is up nearly 16 percent to date. Dominic Chu looks at whether there's still more room to run.
CSL has warned of a "biotech bubble" amid a frenzy of mergers and acquisition activity across the healthcare sector, the Financial Times reports.
The Nasdaq biotech ETF IBB is coming back after tumbling more than 4 percent toward the end of last week. Is now the time to buy, with Eric Schmidt, Cowen & Co., and John Sonnier, with William Blair & Co.
A major deal in the pharma space, Teva says it will buy Allergan's generics business in a deal worth a little over 40 billion dollars. CNBC's Meg Tirrell reports the details.
Insight on malaria prevention, with Monceff Slaoui, GlaxoSmithKline, who is committed to the social responsibility of saving lives.
Biotech is going to break out, RBC Capital Markets' Michael Yee said. There are the names on his buy list.
CNBC's Meg Tirrell dives into how J&J plans to tackle autoimmune disease and why health care professionals say the microbiome "is going to change the face of human health."
In terms of deal value, healthcare has logged the most M&A activity this year, according to Dealogic, after taking the top spot in both 2014 and 2013. CNBC's Morgan Brennan reports.
Seres Therapeutics has filed to go public, ticker MCRB (for microbiome). CNBC's Meg Tirrell explains why it has breakthrough therapy designation from the FDA.
Avalanche Biotechnologies fell 56 percent, but CEO Thomas Chalberg declined to say whether he would buy more shares.
Margaret Patel, senior portfolio manager & managing director at Wells Fargo Advantage Funds, explains why she likes U.S. pharmaceutical stocks.
David Seaburg of Cowen has a way to trade pharma stocks into the ASCO meeting. He breaks it down, with Stacey Gilbert of Susquehanna and Brian Sullivan.
CHICAGO, May 14- Genome pioneer J. Craig Venter's company has signed a broad collaboration agreement with the Cleveland Clinic to sequence and analyze de-identified blood samples from the health system's patients, the two parties said on Thursday. The deal is the latest in a string for Venter's La Jolla, California- based Human Longevity Inc, a start-up formed in...
--Amgen in late 2012 bought Decode Genetics for $415 million in cash to gain access to a database of complete genetic sequences of 2,636 Icelanders. --In January 2014, Regeneron Pharmaceuticals Inc signed a deal with Geisinger Health System in Pennsylvania to sequence DNA from as many as 250,000 volunteers from Geisinger's pool of 3 million patients.
Regeneron Pharmaceuticals Inc, which signed a deal with Pennsylvania's Geisinger Health System in January 2014 to sequence partial genomes of some 250,000 volunteers, is already claiming discoveries based on the new approach. Pfizer Inc, Roche Holding AG and Biogen Inc are working on similar projects that use DNA and patient health data to find new drug...